Dr. Sallman on the Responses to PRGN-3006 in Select AML and Higher-Risk MDS

Video

In Partnership With:

David Sallman, MD, discusses responses achieved a first-in-human dose escalation/dose expansion phase 1/1b clinical trial of an UltraCAR-T agent, PRGN-3006, in patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome with hypomethylating agent failure.

David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, discusses responses achieved in a first-in-human dose escalation/dose expansion phase 1/1b clinical trial (NCT03927261) of an UltraCAR-T agent, PRGN-3006, in patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome with hypomethylating agent failure.

A cohort of 6 patients who received lymphodepletion with fludarabine 30 mg/m2 and cyclophosphamide at 500 mg/m2 on days -5 to -3 and PRGN-3006 experienced encouraging responses with the agent, according to Sallman. Specifically, 3 patients achieved a response to treatment based on European LeukemiaNet criteria, Sallman says.

One patient subsequently underwent a successful allogeneic stem cell transplant (ASCT) and experienced a complete response (CR) with hematologic recovery for over 1 year, Sallman explains. Another patient with extramedullary AML achieved a partial response at day 28, Sallman adds. This patient may be the first with myeloid sarcoma to receive treatment with a novel CAR T-cell therapy, according to Sallman. A third patient, who experienced a post-ASCT relapse, achieved a CR with incomplete hematological recovery; this response also persisted for approximately 3 months, Sallman says.

These are early data with PRGN-3006, but they are intriguing and more information on this approach is anticipated, Sallman concludes.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD